Top Multinational Pharma Interested in Assessing/Onboarding ACT and/or Other IO Modalities; IO Landscape, Portfolio Gap Analysis, and BD Strategy Assessment

The Client

• Top 10 multinational Biopharma, historically a leading oncology player with a strong cash position and biologics-based clinical-regulatory and commercial infrastructure
• Looking to understand how/where to be positioned within the rapidly evolving competitive IO landscape

Challenge

• Client missed the first IO wave (anti-PD1 mAbs), now seeking to ensure their current/future R&D and BD strategy is optimally aligned with emerging competitive and commercial opportunities in solid tumors
• Lacking consensus needed to address looming oncology portfolio gap (early/mid-stage clinical candidates)

Approach

• Provided a comprehensive and multifactorial assessment of the evolving scientific, clinical, competitive, regulatory, reimbursement, and commercial landscape
• Individual discussions and multiple on-site workshops
• Deep-dive on technical details and strategic implications for emerging modalities including ACT, bsAbs, and OVs

Valued Outcome

• Provide recommendations on prioritization of in-house assets, ongoing partnerships, and external opportunities within attractive and feasible settings and platforms
• Recommendations supported by extensive competitive and scientific analyses, CHBC expertise, and discussions with key client-company stakeholders